Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBLTG.L Regulatory News (BLTG)

  • There is currently no data for BLTG

Board Changes

8 Feb 2011 07:00

RNS Number : 8325A
Regenersis PLC
08 February 2011
 

8 February 2011

 

 

Regenersis plc 

("Regenersis" or the "Group")

Board Changes 

Regenersis plc (LSE AIM: RGS), a strategic outsourcing partner to many of the world's leading consumer technology companies, announces a number of changes to its Board of Directors (the "Board"). 

Jeff Hewitt, David Holland and David Gilbert have today stepped down from their respective Non-Executive positions on the Board. 

In turn, the Board has appointed Matthew Peacock as Non-Executive Chairman and Michael Peacock and Andrew Lee as Non-Executive Directors.   

These changes to the Board take effect immediately.

Matthew Peacock is the founder partner of Hanover Investors Management LLP which is significant shareholder of Regenersis. Hanover Investors is a specialist turnaround investment firm based in London. Matthew has led investments for over 20 years in, amongst other sectors, manufacturing, outsourced business services, chemicals, financial services, textiles and logistics. Prior to this, he ran the International M&A team in London at Barclays de Zoete Wedd's, having started his career at Credit Suisse First Boston, in New York. He holds a Masters degree in Law from Cambridge University. Matthew is also Chairman of Fairpoint Group plc and Singer Capital Markets Limited, a London stockbroking and corporate advisory firm, and a Non-Executive Director of STV Group plc. 

Michael Peacock was most recently the Finance Director at Victrex plc. Victrex is a global manufacturer of innovative, high performance thermoplastic polymers, working with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Michael was formerly with Barclays de Zoete Wedd's corporate finance department before moving into industry as a Finance Director, initially with Viva! Health and Leisure Clubs Limited.

Andrew Lee served as Managing Director of marketing and logistics service provider Dataforce Group Limited from 2004, successfully selling the business to Twenty plc in 2006 and becoming a director of Twenty plc. Prior to that, he spent four years as Group Operations Director of N Brown Group plc, a UK catalogue and internet clothes retailer with an £800 million market capitalisation, and 15 years in the Unipart Group where he became managing director of Demand Chain Logistics. 

Matthew Peacock and Michael Peacock are not related.

Gary Stokes, Chief Executive Officer of Regenersis, said: 

"I would like to thank the outgoing Non-Executive Directors for their excellent contribution and wish them all the best for the future.

"I very much look forward to drawing on the support and experience of our new Board members." 

The following information is provided in compliance with the provisions of Schedule 2(g) of the AIM Rules for Companies:

Matthew Roy Peacock (age 49), as a partner in Hanover Investors Management LLP, has an indirect holding of 6,347,500 ordinary shares equating to 14.16 per cent. of the issued share capital of the Company. 

Matthew Peacock has been a director or partner of the following companies during the past five years:

Current
Previous
Hanover Investors LLP
TDX Group Limited
Hanover Investors Limited
Elementis PLC
Hanover General Partner
Cosalt PLC
Hanover Investors Management (Cayman) Limited
Iforce Group Limited
Renold PLC
Plasmon PLC
STV Group PLC
 
Fairpoint Group PLC
 
Singer Capital Markets Limited
 
Umbria Corp Srl
 
Dauphin Capital General Partner Limited
 
 
 
 

Matthew Peacock was a director of Plasmon PLC from 18 May 2007 to 23 May 2008. In October 2008 Plasmon PLC was put into administration.

There are no further disclosures to be made in respect of Mr Matthew Peacock under the provisions of paragraph g of Schedule Two of the AIM Rules for Companies. 

Michael William Peacock (age 52) has been a director or partner of the following companies during the past five years:

Current
Previous
None
Victrex plc
 
Victrex Manufacturing Limited
 
Victrex Trustee Limited
 
Victrex Sales Limited
 
 
 

In 1991 Michael Peacock became Group Finance Director of Peaco Sport Limited ("Peaco"). As part of his role, in April 1992, he was appointed a Director of Running Wild Limited, a non-core business that had been acquired as part of a group of companies by Peaco in 1991. Michael Peacock's role at Running Wild was to wind down its remaining insignificant trading operations and to put it into liquidation. Running Wild was placed into creditors voluntary liquidation in December 1992, the principal creditor being another wholly owned subsidiary of Peaco.

There are no further disclosures to be made in respect of Mr Michael Peacock under the provisions of paragraph g of Schedule Two of the AIM Rules for Companies. 

Andrew Stephen Lee (age 52) has been a director or partner of the following companies during the past five years:

 

Current
Previous
Hallidays Hydropower Limited
Cosalt Holiday Homes Limited
 
Twenty plc
 
Dataforce Group Limited
 
 
 

There are no further disclosures to be made in respect of Mr Andrew Lee under the provisions of paragraph g of Schedule Two of the AIM Rules for Companies.

 

 

Enquiries:
 
Regenersis plc +44 (0) 1865 471900
Gary Stokes / Jeremy Wilson
Arden Partners plc +44 (0) 121 423 8900
Steve Douglas
 
Financial Dynamics +44 (0)20 7831 3113
Matt Dixon / Nicola Biles / Charles Palmer

 

 

 

Ends

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAZMGGZLNMGMZM
Date   Source Headline
4th Oct 20185:41 pmRNSHolding(s) in Company
25th Sep 20187:00 amRNSFinal Results
27th Jul 20189:14 amRNSHolding(s) in Company
26th Jul 201811:00 amRNSDirector/PDMR Shareholding
11th Jul 20187:00 amRNSAppointment of Chief Financial Officer
11th Jul 20187:00 amRNSTrading Update and Notice of Results
29th Jun 20188:59 amRNSHolding(s) in Company
13th Jun 201812:16 pmRNSHolding(s) in Company
12th Jun 201812:28 pmRNSHolding(s) in Company
18th Apr 20182:40 pmRNSHolding(s) in Company
18th Apr 201812:05 pmRNSHolding(s) in Company
29th Mar 201811:40 amRNSDirector/PDMR Shareholding
28th Mar 20187:00 amRNSAppointment of Chief Executive Officer
26th Mar 201812:04 pmRNSHolding(s) in Company
22nd Mar 20182:27 pmRNSHolding(s) in Company
20th Mar 20187:11 amRNSHalf-year Report
9th Feb 201812:31 pmRNSDirector/PDMR Shareholding
19th Jan 201810:27 amRNSHolding(s) in Company
19th Jan 20187:00 amRNSTrading Update and Notice of Results
19th Dec 20175:35 pmRNSResult of AGM
24th Nov 20172:48 pmRNSPosting of Annual Report & Notice of AGM
8th Nov 20172:05 pmRNSSecond Price Monitoring Extn
8th Nov 20172:00 pmRNSPrice Monitoring Extension
7th Nov 20177:00 amRNSFinal Results
6th Nov 201710:25 amRNSHolding(s) in Company
3rd Nov 20175:03 pmRNSNotice of Results
13th Oct 20171:01 pmRNSHolding(s) in Company
2nd Oct 20177:00 amRNSPreparation of preliminary results
27th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 20175:54 pmRNSHolding(s) in Company
7th Sep 20177:00 amRNSBoard Update
4th Sep 20177:00 amRNSUpdates on revenue and management
3rd Aug 201712:37 pmRNSHolding(s) in Company
11th Jul 20173:33 pmRNSHolding(s) in Company
6th Jul 20177:00 amRNSTrading Statement
6th Jun 20173:16 pmRNSHolding(s) in Company
30th May 20177:00 amRNSDirectorate Change
16th May 20177:00 amRNSUpdate on Ordinary Shares
12th May 20173:53 pmRNSHolding(s) in Company
10th May 20173:34 pmRNSDirector/PDMR Shareholding
9th May 201712:27 pmRNSDirector/PDMR Shareholding
9th May 201712:26 pmRNSHolding(s) in Company
4th May 20177:00 amRNSResult of Placing
3rd May 20175:04 pmRNSProposed Placing
26th Apr 20176:01 pmRNSHolding(s) in Company
25th Apr 20177:00 amRNSQ3 Trading Update, Cash Flow Review and Funding
15th Mar 20172:55 pmRNSHolding(s) in Company
15th Mar 201711:27 amRNSDirector/PDMR Shareholding
15th Mar 20177:00 amRNSDirector/PDMR Shareholding
14th Mar 20172:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.